Project Grant R01NS137290

Award Date 5/1/24
Completion Date 4/30/29
Dollars Obligated $1.4M
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
미국 뉴욕
Similar Awards
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) Federal Grant Program provides $120,504 to Carnegie Mellon University to develop Peptide Nucleic Acid (PNA) probes that can be used to monitor and disrupt the formation of biomolecular condensates implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create PNA-based tools that can (a) fluorescently label RNAs...
This $1,938,189 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports research into the mechanisms and toxicity of chimeric dipeptide repeat (CDPR) proteins in C9-related amyotrophic lateral sclerosis (C9ALS) and frontotemporal dementia (C9FTD). The research aims to: 1) identify the complexity, extent, and mechanism of CDPR pathology in C9ALS/FTD, 2) investigate the molecular consequences and neuronal toxicity of specific CDPR species in vitro...
This $782,495 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University aims to develop a novel positron emission tomography (PET) ligand that can quantify levels of the protein Poly(ADP-ribose) Polymerase-1 (PARP1) in the living brain. PARP1 dysregulation has been implicated in Alzheimer's disease and other neurodegenerative disorders, but current methods are limited in their ability to study PARP1 in vivo. The project will design and evaluate a...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $1,504,638 in funding to the University of Utah to conduct research on the role of the PASK kinase in modulating autophagy and TDP-43 proteinopathy as potential therapeutic targets for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and spinocerebellar...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $460,625.00 to the University of Massachusetts Medical School to investigate the roles of the deubiquitylation pathway in TDP-43 pathology related to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The 2-year project, running from June 2025 to May...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $236,668 to investigate the impact of the C9ORF72 genetic mutation on the chromatin remodeling BAF complex and its role in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The awardee, Cleveland Clinic Lerner College of Medicine of Case Western Reserve...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,373,307 to The University of Texas Permian Basin (UTPB) to investigate the molecular mechanisms by which the protein PSAP contributes to the pathogenesis of amyotrophic lateral sclerosis (ALS). The research aims to elucidate how PSAP functions as a key molecule linking cell...
This $1,157,896 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at Brown University focused on elucidating the mechanistic basis of transketolase-mediated suppression of neurodegeneration in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). The grantee will study multiple models of ALS/FTD using Drosophila genetics and analyze molecular readouts such as redox state, autophagy,...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of the C-JUN/TE/cGAS/STING pathway in C9ORF72-associated amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). The $697,907 award, with a project period from September 2024 to August 2029, aims to: 1) identify...

MULTIPLEXED QUANTIFICATION OF THE PROTEIN POLY-ADP-RIBOSYLATION LANDSCAPE IN C9ORF72-ALS/FTD - PROJECT SUMMARY PARP1 IS A NUCLEAR PROTEIN THAT IS CRITICALLY INVOLVED IN CELL STRESS RESPONSES. ITS MAIN ENZYMATIC FUNCTION IS TO CATALYZE A PROTEIN POSTTRANSLATIONAL MODIFICATION (PTM) KNOWN AS POLY-ADP-RIBOSYLATION (PARYLATION). IN RESPONSE TO GENOTOXIC STRESS, PARP1 BINDS TO NICKED DNA AND IS RAPIDLY ACTIVATED, RESULTING IN THE SYNTHESIS OF A LARGE NUMBER OF PARYLATED PROTEINS AND INITIATION OF THE DNA DAMAGE REPAIR (DDR) MECHANISMS. RECENT EVIDENCE SUGGESTS THAT PARYLATION SERVES AS A DEATH SIGNAL IN NEURONS. IMPORTANTLY, GENETIC DELETION OR PHARMACOLOGICAL INHIBITION OF PARP1 OFFERS PROFOUND PROTECTION AGAINST BRAIN DYSFUNCTION IN THE ANIMAL MODELS OF MANY DEMENTIAS, INCLUDING ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS/ALS AND FRONTOTEMPORAL DEMENTIA/FTD. C9ORF72 REPEAT EXPANSION IS THE MOST COMMON GENETIC CAUSE OF BOTH AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA. PARP1 IS A COMMON DISEASE MODIFIER OF C9ORF72-ALS/FTD, THE INHIBITION OF WHICH (BY PHARMACOLOGICAL AND GENETIC APPROACHES) AMELIORATES NEURODEGENERATION IN VARIOUS MODELS OF C9ORF72-ALS/FTD. FURTHERMORE, RECENT STUDIES HAVE SHOWN THAT INCREASED PARYLATION IS A COMMON PATHOLOGICAL FEATURE OF ALS/FTD REGARDLESS OF THE UNDERLYING GENETIC CAUSES. DESPITE THESE FINDINGS, THE PARYLATION LANDSCAPE IN C9ORF72-ALS/FTD IS POORLY DEFINED, AND THE UNDERLYING MECHANISM BY WHICH DEREGULATED PARYLATION CONTRIBUTES TO C9ORF72-ALS/FTD IS ELUSIVE. TO ADDRESS THIS, WE WILL LEVERAGE OUR PUBLISHED WORK AND THE EXTENSIVE EXPERIENCE OF MY LAB. PARYLATION IS A NOTORIOUS PTM FOR MASS SPECTROMETRISTS, BECAUSE OF ITS LABILE AND HETEROGENOUS NATURE. WE RECENTLY WERE ABLE TO OVERCOME THESE CHALLENGES, AND DEVELOP A LARGE-SCALE MASS SPECTROMETRIC APPROACH TOWARDS COMPREHENSIVE CHARACTERIZATION OF THE ASP- AND GLU-PARYLATED PROTEOME. FURTHERMORE, WE HAVE ELUCIDATED THE SITE-SPECIFIC FUNCTION OF THE PARYLATION EVENTS ON MANY IMPORTANT SIGNALING PROTEINS. BASED ON THESE RESULTS, WE WILL DEVELOP A "BAR-CODING" SYSTEM FOR THE MULTIPLEXED PARYLATION PROTEOMIC ANALYSES. USING THIS APPROACH, WE WILL DEFINE, IN A GLOBAL, QUANTITATIVE AND SITE-SPECIFIC MANNER, THE PARYLATION LANDSCAPE IN C9ORF72-ALS/FTD (AIM 1). THEN WE WILL GENERATE THE GLOBAL PROTEIN EXPRESSION PROFILES OF C9ORF72-ALS/FTD INDUCED PLURIPOTENT STEM-CELL-DERIVED NEURONS (IPSNS), AND IDENTIFY THE CELL-SPECIFIC PARYLATION EVENTS THAT ARE DRIVEN BY CELL-SPECIFIC EXPRESSION PATTERNS VS. CELL-SPECIFIC REGULATORY MECHANISMS (AIM 2). FINALLY, WE WILL DEPLOY BIOINFORMATIC TOOLS TO IDENTIFY THE POTENTIALLY FUNCTIONALLY IMPORTANT PARYLATED PROTEINS. THESE HIGH PRIORITY HITS WILL BE SUBJECT TO BIOCHEMICAL AND CELL BIOLOGY ASSAYS TO UNDERSTAND THEIR ROLES IN C9ORF72-ALS/FTD. WE WILL ALSO DESIGN AND GENERATE A WEB PORTAL FOR THE DISSEMINATION OF THE QUANTITATIVE PROTEOMIC RESULTS (AIM 3). THE INFORMATION GARNERED FROM THESE STUDIES WILL PROVIDE A FUNDAMENTAL UNDERSTANDING OF THE ROLE OF PARYLATION IN C9ORF72-ALS/FTD, PAVING THE WAY FOR TARGETING THIS PATHWAY FOR THE TREATMENT OF C9ORF72-ALS/FTD, AND MORE BROADLY, THE OTHER RELATED DEMENTIAS.

Posted 4/12/24, 12:00 AM